Get ready for BIO 2024 from June 3-6!
2024-06-01 / GlobalBio & Investment
ExcitingNews!GetreadyforBIO2024fromJune3-6!The#Globalbioteamisheadingtheretobringyouthelatestupdatesandexclusivefirst-handnews!!CheckoutourBIO2024section:https://reurl.cc/AjXp5eReadmore:TaiwanExpertst...
10/30《生技股動態》
2024-10-30 / 新聞中心
市場觀測:✔強生製藥(4747)與耀勝電子換股,擴大雙方在生技醫療產業佈局✔新穎生醫(6810)與韓國商BoditechMed簽訂技術授權合約✔威健生技(6661)與癌症液態活檢公司GuardantHealth簽訂獨家代理合約✔逸達(6576)向美國FDA提交前列腺癌新劑型新藥CAMCEVI3個月劑型新藥申請✔三鼎生技(6808)業務部副總經理吳宸稻轉任顧問,異動為邱文彬✔加捷生醫(4109)董事...
美癌症登月計畫建構腫瘤3D圖譜!最新12篇研究登《Nature》
2024-10-31 / 記者 李林璦
美國時間30日,美國癌症研究所(NCI)癌症登月計畫(CancerMoonshot)中的人類腫瘤圖譜網絡(HumanTumorAtlasNetwork,HTAN)在《Nature》上發表了12篇論文,總共分析人類和動物數十萬個細胞,創建出腫瘤細胞的3D圖譜,並建構了「分子鐘(molecularclock)」來追蹤癌症的細胞變化。 HTAN是在2018年9月啟動,透過NCI的癌症登月計畫提供資金,目...
Leadgene Biomedical, Inc.'s LEADGENE® IS ELISA Kit has been approved by Taiwan's FDA...
2024-02-28 / GlobalBio & Investment
#TFDAApprovalExcitingnews!LeadgeneBiomedical,Inc.'sLEADGENE®IndoxylSulfate(IS)ELISAKit,aCE-markedprotein-boundtoxindiagnosiskit,hasbeenapprovedbyTaiwan'sFDAasaClassIIIinvitrodiagnosticdevi...
竟天膝蓋骨關節炎新藥 澳洲臨床二期收案超過85%、明年規劃三期啟動授權
2024-10-30 / 記者 彭梓涵
今(30)日,竟天生技(6917)宣布,治療膝蓋骨關節炎新藥APC201的澳洲臨床二期試驗推進順利,目前收案超過85%,今年底前完成全部受試者收案目標不變,明年第一季將有初步數據結果,屆時將規劃進行全球多中心臨床三期試驗,並同步尋求國際授權與合作的機會。竟天指出,目前在美國被核准治療骨關節炎藥物濃度最高、效果較佳的非類固醇消炎產品(NSAID)產品為Diclofenac2%溶液劑,也是目前美國同成...
Chang Gung Medical Foundation teams up with Gilead Sciences to accelerate early-stage clinical trial
2024-02-28 / GlobalBio & Investment
**#ClinicalTrials**ChangGungMedicalFoundationteamsupwithGileadSciencestoaccelerateearly-stageclinicaltrials,focusingon#oncology.Thecollaborationaimstoadvanceclinicaltrialsintumorresearch,preclinicalco...
2024 FHED成大匯聚33國生醫專家 共建永續智慧醫療合作生態系
2024-10-29 / 記者 李林璦
10月28日到11月1日,2024未來照護與經濟發展國際會議(2024FHED)在國立成功大學盛大舉行,該會議由成大前瞻醫療器材科技中心主辦,今年以「從醫院到居家的數位健康科技應用(DigitalHealthTechfromHospitaltoHome)」為題,匯聚來自33國、200人次以上的學術領袖、醫師、新創及產業界專家,透過了解當前醫療創新技術趨勢,共同探討在宅醫療科技未來照護需求,期望能建...
Nine biopharma companies have announced record-high revenues for January
2024-02-28 / GlobalBio & Investment
#BiotechGrowthExcitingnewsfromthe#biopharmasector!Ninebiopharmacompanieshaveannouncedrecord-highrevenuesforJanuary,indicatingaprosperousstarttotheyear.Amongthem,AnxoPharmaceuticalTaiwanCo.Ltd(6677.TWO...
AnBogen Therapeutics hits a milestone: completes USD 12.5M Series A funding round!
2024-02-28 / GlobalBio & Investment
**AnBogenTherapeuticshitsamilestone:completesUSD12.5MSeriesAfundinground!**InastrategicmoveledbyCDIBCapitalInternationalCorporation,AnBogenTherapeuticsproudlyannouncesthesuccessfulclosureofitsSeriesAf...
The potential of next-generation microbiome therapy in clinical applications (8th AMC)
2024-02-28 / GlobalBio & Investment
*#MicrobiomeTherapy**Canthegutmicrobiotarevolutionizecancertreatment?Insightsfromthe8thAsiaMicrobiomeConference(#AMC),heldbyIBCAcademiaSinica,NationalTaiwanUniversityHospital,and圖爾思生物科技BIOTOOLSCO.,LTD...
GBI Spotlight: Dr. Han-Chung Wu
2024-02-28 / GlobalBio & Investment
#GBISpotlight:Dr.Han-ChungWu(吳漢忠)MeetDr.Han-ChungWu,themanbehindthedevelopmentofprecisiontherapythroughinnovativephagedisplaytechnology.AstheDirectorofBioTrecatNBRP,AcademiaSinica,heisawell-knownfigur...